JP2024536733A - コロナウイルス融合タンパク質 - Google Patents

コロナウイルス融合タンパク質 Download PDF

Info

Publication number
JP2024536733A
JP2024536733A JP2024514688A JP2024514688A JP2024536733A JP 2024536733 A JP2024536733 A JP 2024536733A JP 2024514688 A JP2024514688 A JP 2024514688A JP 2024514688 A JP2024514688 A JP 2024514688A JP 2024536733 A JP2024536733 A JP 2024536733A
Authority
JP
Japan
Prior art keywords
seq
fusion protein
protein
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024514688A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024536733A5 (enExample
Inventor
オブリー，ニコラス
ブルサン，ファニー
ラクリフ，ジネブ
ディミア－ポアソン，イザベル
エパダウド，マシュー
カーペンティア，ロドルフ
トウゼ，アントワーヌ
メヴェレク，マリー－ノエル
Original Assignee
ユニベルシテ デ トゥール
インスティトュート ナシオナル ドゥ ルシェルシェ プル ラグリキュルテュール，ラリマンタスィヨン エ ランヴィロンヌマン
ユニバーシティ デ リール
インスティテュート ナショナル デ ラ サンテ エ デ ラ ルシェルシュ メディカル
センター ホスピタリエ ウニベルシテール デ リール
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニベルシテ デ トゥール, インスティトュート ナシオナル ドゥ ルシェルシェ プル ラグリキュルテュール，ラリマンタスィヨン エ ランヴィロンヌマン, ユニバーシティ デ リール, インスティテュート ナショナル デ ラ サンテ エ デ ラ ルシェルシュ メディカル, センター ホスピタリエ ウニベルシテール デ リール filed Critical ユニベルシテ デ トゥール
Publication of JP2024536733A publication Critical patent/JP2024536733A/ja
Publication of JP2024536733A5 publication Critical patent/JP2024536733A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
JP2024514688A 2021-09-07 2022-09-07 コロナウイルス融合タンパク質 Pending JP2024536733A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21306220.1 2021-09-07
EP21306220 2021-09-07
PCT/EP2022/074845 WO2023036814A1 (en) 2021-09-07 2022-09-07 Coronavirus fusion protein

Publications (2)

Publication Number Publication Date
JP2024536733A true JP2024536733A (ja) 2024-10-08
JP2024536733A5 JP2024536733A5 (enExample) 2025-09-16

Family

ID=78332732

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024514688A Pending JP2024536733A (ja) 2021-09-07 2022-09-07 コロナウイルス融合タンパク質

Country Status (4)

Country Link
US (1) US20240424086A1 (enExample)
EP (1) EP4399219A1 (enExample)
JP (1) JP2024536733A (enExample)
WO (1) WO2023036814A1 (enExample)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1488646A (zh) * 2003-07-03 2004-04-14 李越希 Sars病毒s蛋白与n蛋白的融合蛋白及其制备、应用
CN111187354A (zh) * 2020-02-20 2020-05-22 北京新创生物工程有限公司 新型冠状病毒(SARS-CoV-2)IgM/IgG抗体检测试剂盒
WO2021163536A2 (en) * 2020-02-14 2021-08-19 Altimmune, Inc. Coronavirus immunogenic compositions and uses thereof
WO2021174128A1 (en) * 2020-02-26 2021-09-02 University Of Maryland, College Park Compositions and methods for mucosal vaccination against sars-cov-2

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806352A (en) 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
FR2815870A1 (fr) 2000-10-27 2002-05-03 Biovector Therapeutics Utilisation de particules hydrophiles associees a des antigenes identiques ou differents pour la preparation de compositions de vaccin

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1488646A (zh) * 2003-07-03 2004-04-14 李越希 Sars病毒s蛋白与n蛋白的融合蛋白及其制备、应用
WO2021163536A2 (en) * 2020-02-14 2021-08-19 Altimmune, Inc. Coronavirus immunogenic compositions and uses thereof
CN111187354A (zh) * 2020-02-20 2020-05-22 北京新创生物工程有限公司 新型冠状病毒(SARS-CoV-2)IgM/IgG抗体检测试剂盒
WO2021174128A1 (en) * 2020-02-26 2021-09-02 University Of Maryland, College Park Compositions and methods for mucosal vaccination against sars-cov-2

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BIORXIV, JPN7026003333, 18 June 2021 (2021-06-18), ISSN: 0005918249 *
CELL REPORTS, vol. 36, JPN6026031271, August 2021 (2021-08-01), pages 109664, ISSN: 0005918250 *
SCIENCE ADVANCES, vol. 7 : eabg7156, JPN7026003332, 28 May 2021 (2021-05-28), pages 1 - 10, ISSN: 0005918248 *

Also Published As

Publication number Publication date
US20240424086A1 (en) 2024-12-26
EP4399219A1 (en) 2024-07-17
WO2023036814A1 (en) 2023-03-16

Similar Documents

Publication Publication Date Title
TWI881117B (zh) 用於預防或治療SARS-CoV-2感染的疫苗組成物
US10960070B2 (en) Prefusion coronavirus spike proteins and their use
JP6048845B2 (ja) ジフテリア毒素の無毒性突然変異体ｃｒｍ１９７又はその断片を含む融合タンパク質
AU2014230822B2 (en) Heat-stable Respiratory Syncytial Virus prefusion F protein oligomers and their use in immunological compositions
RU2723039C2 (ru) Мутанты белка f rsv
EP3054971B1 (en) Epstein-barr virus vaccines
JP2023513693A (ja) ＳＡＲＳ－ＣｏＶ－２ワクチン
TW202140519A (zh) 疫苗
KR20220010478A (ko) 기도 감염의 치료 또는 예방용 서브유닛 백신
JP2018520159A (ja) Ｒｓｖに対するワクチン
AU2007239354A1 (en) N protein fusion proteins of a virus in the Paramyxoviridae-protein of interest family
WO2001045639A2 (en) Methods for protecting against lethal infection with bacillus anthracis
US20240082387A1 (en) Fusion protein comprising coronavirus-derived receptor-binding domain and nucleocapsid protein, and use thereof
WO2023138334A1 (zh) 一种重组新型冠状病毒蛋白疫苗、其制备方法和应用
PH12015500890B1 (en) Vaccine for preventing porcine edema disease
JP2026062907A (ja) 流行性耳下腺炎ウイルスおよび麻疹ウイルスの免疫原およびそれらの使用
CN102711818B (zh) 抗rsv免疫原和免疫方法
WO2023138333A1 (zh) 一种重组新型冠状病毒蛋白疫苗、其制备方法和应用
US20240424086A1 (en) Coronavirus fusion protein
JP2023544250A (ja) インフルエンザ菌ワクチン及びその使用方法
KR20220040423A (ko) 재조합 단백질을 포함하는 사스-코로나바이러스-2 감염증 예방 또는 치료용 백신 조성물
KR102859798B1 (ko) 중동호흡기증후군 코로나바이러스에 대한 t-세포 에피톱 기반의 펩타이드 백신 및 이의 용도
RU2788403C2 (ru) Мутанты белка f rsv
JP2024545462A (ja) ワクチン組成物及びそれらの使用
HK40120558A (en) Respiratory syncytial virus f protein and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250904

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250904

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260715

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260728